Publications by authors named "John Paul Seenan"
Background: Exclusive enteral nutrition is an established treatment for active Crohn's disease (CD) but the role of partial enteral nutrition (PEN) in the broader management of the disease is less clear. This systematic review and meta-analysis reviewed the literature on the role of PEN in CD management.
Methods: This review was conducted following Cochrane recommendations.
Background: The immunological effects of treatment with exclusive enteral nutrition (EEN) in Crohn's disease (CD) remain unknown. We characterized the plasma levels of inflammation-related proteins (IRPs) in children with CD and ulcerative colitis (UC) compared with noninflammatory controls (non-IBD) and explored the effect of EEN in CD.
Methods: Ninety-two IRPs were quantified using Olink proteomics in children with CD (n = 53), UC (n = 11), and non-IBD (n = 19).
Background: Exclusive enteral nutrition (EEN) and partial enteral nutrition (PEN) remain the only established dietary therapies in Crohn's disease (CD) management. We conducted a questionnaire survey to evaluate the perceptions of adults with CD toward established and emerging food-based dietary therapies.
Methods: A 26-question anonymous survey was mailed to 300 adults receiving biologic treatment.
We present a patient with a drug-induced liver injury with autoimmune features as a result of infliximab therapy for ulcerative colitis. This is a rare but serious side effect in patients receiving this treatment which clinicians should consider in the event of liver function test derangement.
View Article and Find Full Text PDFBackground And Aims: Micronutrient deficiencies are common in patients with inflammatory bowel disease (IBD), but whether they relate to disease outcomes remains unknown. This study assessed the micronutrient status of adults with IBD on treatment with biologic therapies and explored predictive relationships with disease outcomes.
Methods: Seventeen micronutrients were measured in the blood of 216 adults with IBD on biologic therapy.
Background And Aims: Treatment adherence is key to the efficacy of exclusive enteral nutrition [100% EN] in active Crohn's disease [CD], but there are no biomarkers to objectively estimate this. We explored faecal parameters as biomarkers of compliance with 100% EN, and subsequently developed and validated the Glasgow Exclusive Enteral Nutrition Index of Compliance [GENIE].
Methods: Healthy adults replaced all [100% EN] or part [85% EN, 50% EN, 20% EN] of their diet with a formula for 7 days.
Article Synopsis
- Anti-drug antibodies linked to treatment failure in inflammatory bowel disease (IBD) patients on anti-TNF agents were analyzed in a large UK study involving 1058 participants.
- The study found that patients who developed antibodies to their first anti-TNF drug were more likely to also develop antibodies to their second anti-TNF drug, indicating a potential pattern of immunogenicity across different treatments.
- Introducing an immunomodulator when switching anti-TNF therapies boosted treatment persistence in patients with immunogenicity, suggesting that combined therapies may enhance outcomes in IBD management.
Background: This updated systematic review and meta-analysis investigates the putative role of the appendix in ulcerative colitis as a therapeutic target.
Methods: Ovid Medline, Embase, PubMed and CENTRAL were searched with MeSH terms ("appendectomy" OR "appendicitis" OR "appendix") AND ("colitis, ulcerative") through October 2020, producing 1469 references. Thirty studies, including 118 733 patients, were included for qualitative synthesis and 11 for quantitative synthesis.
We present a patient with an acute kidney injury thought secondary to acute interstitial nephritis as a result of vedolizumab maintenance therapy for Crohn's disease. This appears to be a rare but serious side effect in patients receiving this treatment which clinicians should consider in the event of renal dysfunction.
View Article and Find Full Text PDFMusculoskeletal deficits are among the most commonly reported extra-intestinal manifestations and complications of inflammatory bowel disease (IBD), especially in those with Crohn's disease. The adverse effects of IBD on bone and muscle are multifactorial, including the direct effects of underlying inflammatory disease processes, nutritional deficits, and therapeutic effects. These factors also indirectly impact bone and muscle by interfering with regulatory pathways.
View Article and Find Full Text PDFArticle Synopsis
- COVID-19 significantly impacted healthcare in 2020, causing over 4.9 million global cases and leading to postponements of elective medical procedures, especially affecting chronic illnesses like inflammatory bowel disease (IBD).
- A sharp decline in testing for biologic therapies, such as adalimumab and infliximab, was noted, with a 75.6% and 36.2% drop respectively, due to the pandemic's restrictions on outpatient care.
- To prevent adverse outcomes for IBD patients, urgent changes in clinical practices are necessary, with a call for further reforms to maintain effective patient-centered care moving forward.
Background And Aim: Ustekinumab is a monoclonal antibody that targets interleukin-12/23. In Scotland, it was approved for the treatment of moderate to severe Crohn's disease in 2017. The objective of this study was to establish the real-world effectiveness and safety of ustekinumab in the treatment of Crohn's disease.
View Article and Find Full Text PDFBackground: Muscle-bone deficits are common in pediatric Crohn's disease; however, few studies have assessed long-term musculoskeletal outcomes in adults with childhood-onset Crohn's disease. This study assessed the prevalence of musculoskeletal deficits in young adults with childhood-onset Crohn's disease compared with healthy controls.
Methods: High-resolution MRI and MR spectroscopy were used to assess bone microarchitecture, cortical geometry and muscle area, and adiposity at distal femur and bone marrow adiposity (BMA) at lumbar spine.
Background: Exclusive enteral nutrition (EEN) is an effective treatment for Crohn's disease.
Aims: To investigate the hypothesis that ingredients of EEN formulas are unlikely to initiate a disease flare and that their dietary elimination is not essential for disease amelioration.
Methods: We performed compositional analysis of EEN formulas with evidence of efficacy in management of active Crohn's disease.
Background & Aims: In the West, a substantial proportion of subjects with adenocarcinoma of the gastric cardia and gastroesophageal junction have no history of reflux. We studied the gastroesophageal junction in asymptomatic volunteers with normal and large waist circumferences (WCs) to determine if central obesity is associated with abnormalities that might predispose individuals to adenocarcinoma.
Methods: We performed a study of 24 healthy, Helicobacter pylori-negative volunteers with a small WC and 27 with a large WC.